Proceedings from the third in a series of 11 integrated webinars held in association with the 2020 ONS Annual Congress. Featuring perspectives from Ms Kim Leake, Ms Mollie Moran, Dr Craig Moskowitz and Dr Michael E Williams.
Introduction (00:00)
Activity and tolerability of polatuzumab vedotin for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (3:25)
Overview of and clinical experience with CAR (chimeric antigen receptor) T-cell therapy for R/R DLBCL (10:45)
Available trial data with brentuximab vedotin as a component of up-front therapy (ECHELON-1) or as consolidation after transplant (AETHERA) for patients with Hodgkin lymphoma (24:29)
Rationale for targeting the PD-1/PD-L1 axis in Hodgkin lymphoma (31:29)
Case (Ms Moran): A woman in her early 30s with Stage IV Hodgkin lymphoma treated with AVD (doxorubicin/vinblastine/dacarbazine) and brentuximab vedotin experiences peripheral neuropathy (34:20)
Observation versus active treatment for patients with asymptomatic follicular lymphoma; use of subcutaneous rituximab (41:31)
Activity and tolerability of lenalidomide/rituximab (R2) compared to rituximab/chemotherapy for untreated advanced-stage follicular lymphoma; approved PI3K inhibitors for R/R disease (49:35)
Initial presentation and management of mantle cell lymphoma; second-line therapy options (BTK inhibitors, R2, venetoclax, et cetera) (1:01:57)
Case (Ms Leake): A man in his early 70s with newly diagnosed mantle cell lymphoma who wishes to avoid chemotherapy receives ibrutinib (1:13:33)
Management of lymphomas in the era of COVID-19 (1:19:04)
Podden och tillhörande omslagsbild på den här sidan tillhör Dr Neil Love. Innehållet i podden är skapat av Dr Neil Love och inte av, eller tillsammans med, Poddtoppen.
